Bristol-Myers Squibb is the famous Corporate Investor, which was founded in 1887. The fund was located in North America if to be more exact in United States. The main department of described Corporate Investor is located in the New York.
The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 3 or 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Health Diagnostics, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Blade Therapeutics, PathAI, Personal Genome Diagnostics (PGD). Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Bristol-Myers Squibb, startups are often financed by Sprout Group, SR One, Refactor Capital. The meaningful sponsors for the fund in investment in the same round are Seventure Partners, Ysios Capital, Yonghua Capital. In the next rounds fund is usually obtained by Partners Investment, Symbiosis Group, Symbiosis.
The top amount of exits for fund were in 2014. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. This Bristol-Myers Squibb works on 2 percentage points more the average amount of lead investments comparing to the other organizations. The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this Corporate Investor is 34 percentage points more often commits exit comparing to other organizations.
The fund was created by John Ripley Myers, William McLaren Bristol.
Related Funds
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
TORL BioTherapeutics | $158M | 10 Apr 2024 | Los Angeles, California, United States | ||
Attralus | $56M | 06 Feb 2024 | San Francisco, California, United States | ||
Cour Pharmaceuticals Development | $105M | 30 Jan 2024 | Elmhurst, Illinois, United States | ||
Ratio Therapeutics | $50M | 17 Jan 2024 | Boston, Massachusetts, United States | ||
GlycoEra | 05 Jan 2024 | Schlieren, Zurich, Switzerland | |||
AstronauTx | $65M | 08 Oct 2023 | United Kingdom, England, United Kingdom | ||
Precede Biosciences | $57M | 05 Oct 2023 | Boston, Massachusetts, United States | ||
ROME Therapeutics | $72M | 12 Sep 2023 | Cambridge, Massachusetts, United States | ||
Cellares | $255M | 23 Aug 2023 | South San Francisco, California, United States |
– TreeFrog Therapeutics, a Bordeaux, France-based biotech startup focused on developing stem cell-derived cell therapies for millions of patients, closed a $75m (€64M) Series B financing round, bringing the total funding to date to $83m (€70m).
– The round was led by Bpifrance Large Venture, part of the French Public Investment Bank, joined by U.S. investment firm Leonard Green & Partners L.P., global pharmaceutical company Bristol Myers Squibb, and European venture capital team XAnge.
– The company intends to use the funds to deploy biomimetic C-StemTM technology for clinical-grade manufacturing, grow and advance to the clinic a comprehensive pipeline of cell therapies, and finance the opening of technological hubs in Boston, MA, and Kobe, Japan.
– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
TORL BioTherapeutics | $158M | 10 Apr 2024 | Los Angeles, California, United States | ||
Attralus | $56M | 06 Feb 2024 | San Francisco, California, United States | ||
Cour Pharmaceuticals Development | $105M | 30 Jan 2024 | Elmhurst, Illinois, United States | ||
Ratio Therapeutics | $50M | 17 Jan 2024 | Boston, Massachusetts, United States | ||
GlycoEra | 05 Jan 2024 | Schlieren, Zurich, Switzerland | |||
AstronauTx | $65M | 08 Oct 2023 | United Kingdom, England, United Kingdom | ||
Precede Biosciences | $57M | 05 Oct 2023 | Boston, Massachusetts, United States | ||
ROME Therapeutics | $72M | 12 Sep 2023 | Cambridge, Massachusetts, United States | ||
Cellares | $255M | 23 Aug 2023 | South San Francisco, California, United States |